Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Bioavailability of a Single Dose 20 mg BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) Following Oral Administration to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Phase I Study)

NCT02171715 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02171715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02171715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Bioavailability of a Single Dose 20 mg BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) Following Oral Administration to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Phase I Study)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2009
Completion date
Not reported
Enrollment
22 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy